Els Everaert

719 total citations
11 papers, 256 citations indexed

About

Els Everaert is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Els Everaert has authored 11 papers receiving a total of 256 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pulmonary and Respiratory Medicine, 4 papers in Oncology and 3 papers in Molecular Biology. Recurrent topics in Els Everaert's work include Prostate Cancer Treatment and Research (3 papers), Glioma Diagnosis and Treatment (2 papers) and Cancer, Lipids, and Metabolism (2 papers). Els Everaert is often cited by papers focused on Prostate Cancer Treatment and Research (3 papers), Glioma Diagnosis and Treatment (2 papers) and Cancer, Lipids, and Metabolism (2 papers). Els Everaert collaborates with scholars based in Belgium, United Kingdom and Spain. Els Everaert's co-authors include Guy Joos, Paul Germonpré, Bart N. Lambrecht, Stephen P. Hunt, Romain Pauwels, Marijke De Veerman, Carmen De Felipe, Kris Thielemans, Frédéric Amant and An Coosemans and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and Journal of Clinical Microbiology.

In The Last Decade

Els Everaert

11 papers receiving 250 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Els Everaert Belgium 7 90 70 67 59 43 11 256
Yingjiang Gu China 10 120 1.3× 24 0.3× 64 1.0× 16 0.3× 30 0.7× 18 316
Yoshiko Hirano Japan 12 33 0.4× 49 0.7× 143 2.1× 41 0.7× 48 1.1× 27 430
Marieke T. de Graaf Netherlands 8 25 0.3× 55 0.8× 69 1.0× 61 1.0× 60 1.4× 10 378
Jinhee Kim South Korea 10 27 0.3× 33 0.5× 86 1.3× 26 0.4× 22 0.5× 24 305
Dong‐Hyuk Sheen South Korea 11 20 0.2× 26 0.4× 93 1.4× 39 0.7× 54 1.3× 17 358
Patricia Calleja Spain 10 25 0.3× 46 0.7× 68 1.0× 14 0.2× 62 1.4× 16 308
Jane Redford United Kingdom 5 76 0.8× 22 0.3× 70 1.0× 53 0.9× 62 1.4× 5 332
Takako Kihara Japan 7 44 0.5× 42 0.6× 46 0.7× 22 0.4× 15 0.3× 36 210
K Hamada Japan 10 80 0.9× 77 1.1× 55 0.8× 56 0.9× 10 0.2× 26 376
Khalid Ibrahim Qatar 13 46 0.5× 52 0.7× 156 2.3× 36 0.6× 16 0.4× 27 395

Countries citing papers authored by Els Everaert

Since Specialization
Citations

This map shows the geographic impact of Els Everaert's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Els Everaert with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Els Everaert more than expected).

Fields of papers citing papers by Els Everaert

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Els Everaert. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Els Everaert. The network helps show where Els Everaert may publish in the future.

Co-authorship network of co-authors of Els Everaert

This figure shows the co-authorship network connecting the top 25 collaborators of Els Everaert. A scholar is included among the top collaborators of Els Everaert based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Els Everaert. Els Everaert is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Rottey, Sylvie, Annouschka Laenen, Emmanuel Seront, et al.. (2025). Optimal treatment duration in metastatic renal cell carcinoma patients responding to immune checkpoint inhibitors: should we treat beyond two years?. Acta Oncologica. 64. 979–988. 1 indexed citations
2.
3.
4.
Boegemann, Martin, Martin Hatzinger, Els Everaert, et al.. (2017). Real-world treatment with abiraterone acetate in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology. 35(6_suppl). 239–239. 1 indexed citations
5.
Laere, Bram De, Peter Van Oyen, Christophe Ghysel, et al.. (2017). Circulating tumour cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.. Journal of Clinical Oncology. 35(15_suppl). 5049–5049. 2 indexed citations
6.
Amant, Frédéric, An Coosemans, Vincent Renard, Els Everaert, & Ignace Vergote. (2009). Clinical Outcome of ET-743 (Trabectedin; Yondelis) in High-Grade Uterine Sarcomas. International Journal of Gynecological Cancer. 19(2). 245–248. 18 indexed citations
7.
Everaert, Els, et al.. (2004). Temozolomide for the Treatment of Recurrent Supratentorial Glioma: Results of a Compassionate use Program in Belgium. Journal of Neuro-Oncology. 70(1). 37–48. 12 indexed citations
8.
Neyns, Bart, et al.. (2004). Temozolomide for the treatment of recurrent glioma: Results of a compassionate use program in Belgium. Journal of Clinical Oncology. 22(14_suppl). 1541–1541. 3 indexed citations
9.
Baère, Thierry de, Els Everaert, G. Wauters, et al.. (2002). Bacteremia Due to Moraxella atlantae in a Cancer Patient. Journal of Clinical Microbiology. 40(7). 2693–2695. 9 indexed citations
10.
Lambrecht, Bart N., Paul Germonpré, Els Everaert, et al.. (1999). Endogenously produced substance P contributes to lymphocyte proliferation induced by dendritic cells and direct TCR ligation. European Journal of Immunology. 29(12). 3815–3825. 143 indexed citations
11.
Germonpré, Paul, Guy Joos, Els Everaert, Johan Kips, & Ruben Pauwels. (1995). Characterization of Neurogenic Inflammation in the Airways of Two Highly Inbred Rat Strains. American Journal of Respiratory and Critical Care Medicine. 152(6). 1796–1804. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yingjiang Gu Breakdown of academic impact, for papers by Yoshiko Hirano Breakdown of academic impact, for papers by Marieke T. de Graaf Breakdown of academic impact, for papers by Jinhee Kim Breakdown of academic impact, for papers by Dong‐Hyuk Sheen Breakdown of academic impact, for papers by Patricia Calleja Breakdown of academic impact, for papers by Jane Redford Breakdown of academic impact, for papers by Takako Kihara Breakdown of academic impact, for papers by K Hamada Breakdown of academic impact, for papers by Khalid Ibrahim
Rankless by CCL
2026